Position in BIIB
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$1,573,997
+$356,136 QoQ
Shares Held
7,285
+9.7% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.25%
of 13F equity value
Holder Rank
#377
of 1,036 holders
Holding Since
Sep 2020
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in BIIB Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Kathmere Capital Management, LLC holds $38,480,404 across 14 Drug Manufacturers - General names. BIIB ranks #8 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
46,204 | $11,734,429 | |
| 2 | LLY |
ELI LILLY & Co
|
4,626 | $5,548,563 | |
| 3 | MRK |
Merck & Co., Inc.
|
30,944 | $3,976,304 | |
| 4 | NVS |
Novartis AG
|
22,990 | $3,602,992 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
26,787 | $3,384,269 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
37,197 | $2,143,291 | |
| 7 | ABBV |
AbbVie Inc.
|
7,045 | $1,772,803 | |
| 8 | BIIB |
Biogen Inc.
This page
|
7,285 | $1,573,997 |
All Filings in BIIB
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,573,997 | 7,285 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $1,217,861 | 6,643 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $843,168 | 4,791 | Shares | Sole | 2026-01-13 | |
| 2025-09-30 | $346,417 | 2,473 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $208,856 | 1,663 | Shares | Sole | 2025-07-16 | |
| 2023-12-31 | $212,191 | 820 | Shares | Sole | 2024-04-16 | |
| 2023-09-30 | $233,108 | 907 | Shares | Sole | 2023-10-11 | |
| 2023-06-30 | $258,358 | 907 | Shares | Sole | 2023-07-11 | |
| 2020-12-31 | $88,639 | 362 | Shares | Sole | 2021-02-16 | |
| 2020-09-30 | $102,692 | 362 | Shares | Sole | 2020-11-20 | |
| No filing history on record for this holder in this stock. | ||||||